

ASIAN JOURNAL OF PHARMACEUTICAL
AND BIOLOGICAL RESEARCH

AJPBR



Indexed by:



Universal
Impact Factor



IMPACT FACTOR
SEARCH

Editorial board

Dr. Madhu Bala Scientist 'F' and Joint Director, Institute of Nuclear Medicine and Allied Sciences (INMAS), India

Dr. Sandip Narayan Chakraborty
Research Asst, Translational Molecular Pathology, Ut Md Anderson Cancer Center, Life Sciences Plaza, Houston, TX 77030

Dr. Tushar Treembak Shelke
Head of Department of Pharmacology and Research Scholar, In Jspms Charak College of Pharmacy & Research, Pune, India

Dr. Subas Chandra Dinda
Professor-cum-Director: School of Pharmaceutical Education & Research (SPER), Berhampur University, Berhampur, Orissa, India.

Dr. Jagdale Swati Changdeo
Professor and Head, Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, S.No.124,MIT Campus,Kothrud, Pune-411038

Dr. Biplab Kumar Dey
Principal, Department of Pharmacy, Assam downtown University, Sankar Madhab Path, Panikhaiti 781026, Guwahati, Assam, India

Dr. Yogesh Pandurang Talekar
Research Associate, National Toxicology Centre

Dr. Indranil Chanda
Assistant Professor, Girijananda Chowdhury Institute of Pharmaceutical Science, Hathkhowapara, Azara Guwahati-17, Assam, India.

Dr. Sudip Kumar Mandal Department of Pharmaceutical Chemistry, Dr. B. C. Roy College of Pharmacy & AHS, Bidhannagar, Durgapur-713206, India.

Sodikova Dilrabokhon Andijan state medical institute

Dr., associate professor **Kuryazova Sharofat** Tashkent Pediatric medical institute

Dr., Abdurakhmanova Nigora Nazimovna Tashkent Pediatric Medical Institute

Abdullaeva Umida Bukhara state medical institute

Dr. Neeraj Upmanyu

Prof., Peoples Institute of Pharmacy & Research Center, Bhopal, MP, India.

Dr. Mirrakhimova Maktuba Khabibullaevna Tashkent medical academy Uzbekistan

Dr. Nishanova Aziza Abdurashidovna, Tashkent State Dental Institute

Dr. Sadikova Minurakhon Adkhamovna Andijan State Medical Institute

Kurbanova Sanobar Yuldashevna Tashkent State Dental Institute

Zokirova Nargiza Bahodirovna Tashkent Pediatric medical institute

Khabilov Behzod Nigmon ugli Tashkent State Dental Institute

Dr. Domenico De Berardis Department of Mental Health, Azienda Sanitaria Locale Teramo, 64100 Teramo, Italy

Dr. Azizova Rano Baxodirovna associate professor of the Department of neurology of the Tashkent Medical Academy

Dr. Ishankhodjaeva Gulchekhra Tashkent Medical Academy

Institute of Nuclear Medicine and Allied Sciences (INMAS), India

Brig SK Mazumdar Marg, Timarpur, New Delhi, Delhi 110054 India

Contrast-induced nephropathy. Focus on prevention.

Mustafayeva Malika Rustamovna.

Bukhara State Medical Institute, Republic of Uzbekistan, Bukhara

Summary: Contrast-induced nephropathy (CIN)- iatrogenic pathology that occurs after introduction of a contrast agent into the body. Known links in the pathogenesis of CIN are direct toxic effects in the renal tissues and decreased hemodynamics in the kidney. Other mechanisms of CIN pathogenesis are still studied not enough. To date, but many definitions of CIN, the most common of which consider an increase in serum creatinine greater than 0.5 mg/dL or more than 25% of the original level, determined during the first 2-3 days after the introduction of contrast substance. CIN is quite rare in the general population of patients, wearing contrast studies, but many fold increases in groups of patients with initial kidney disease in diabetic patients and the elderly. Multiple risk factors greatly increases the chance of developing CIN. The best ways to prevent CIN consider active identification of patients with risk factors, and adequate periprocedural hydration. The role of various drugs in prevention of contrast-induced nephropathy is still debatable and suggests a further research. In this clinical practice for the prevention of CIN should be pre-read isosmolar and low osmolar contrast agents, strictly avoiding highly osmolar contrast agents in patients with impaired renal function, despite the ongoing discrepancies regarding the degree of nephro-toxicity of various contrast agents.

Keywords: contrast agents, serum creatinine (Cr), creatinine clearance (CC), glomerular filtration rate (GFR), contrast-induced nephropathy (CIN).

Increased use of contrast substances for diagnostic and therapeutic radiological procedures has led to an increase number of cases of contrast-induced nephropathy (CIN) - iatrogenic pathology, associated with the introduction into the body of contrast substance.

CIN is a complex acute renal failure syndrome. Insufficiency, developing after the introduction of

iodine-containing contrast agents. The definition of CIN includes absolute or

a relative increase in the level of creatinine on blood serum after contrast injection

compared with baseline creatinine on, when other causes of violation are excluded renal function. Increasing creatinine levels observed within 24-48 hours after the introduction

contrast ratio, peak creatinine noted 3-5 days after the procedure and return to normal or close to normal level occurs within 1-3 weeks (1). The size of the increase in the level of creatinine, which determines CIN, differs from research to research (from

20 to 50% or in absolute terms - from 0.5 to 1.0 mg / dl), making it difficult to compare their results. Most general definition, most commonly used recently, is more than 25% relative increase or more than 0.5 mg/dL absolute increase in serum creatinine from the initial value within 48-72 hours after injection of contrast into the body. Based on given this definition, the frequency of CIN in the total populations are reported to fluctuate from 1.2 to 1.6% (2,3). CIN frequency is even higher in patients with various cardiovascular pathology, which is not surprising, given the high how many risk factors for the development of CIN in this group of patients. According to the Mayo Clinic (Mayo) incidence of CIN in 7586 patients, who underwent percutaneous coronary interventions (PCI) was 3.3% (4). In relation very small study by McCullough and et al. (5) where the data was analyzed 1826 patients undergoing PCI, CIN was registered in 14.5% of cases. Hemodialysis in these two studies, it was required respectively, in 0.7% and 0.3%.

PATHOGENESIS OF CONTRAST-INDUCED NEPHROPATHY.

The pathogenesis of CIN is not fully understood. Until now time, several pathophysiological

biological mechanisms of CIN, including direct toxic effect on the renal canal annular epithelium, oxidative stress, ischemical injury and tubular obstruction(6,7). Domestic (8) and foreign nephro-logs (9) believe that radiopaque media-on the one hand, after a short period

vasodilation is caused with the participation of renin-angiotensin system spasm leading arterioles, and on the other hand, increasing blood viscosity, disrupt microcirculation and have an adverse effect on medium toxic effect on the canal annular epithelium, probably by generating oxygen free radicals (8,9). Short blood flow in the medullary layer of the kidney, leading to leading to his hypoxia, could be the result of an increase peripheral hydrostatic pressure and secondary pressure increase in tubules due to contrast-induced diu-cut, vasoconstriction due to excess vasoac-active substances such as adenosine and endothelin and

reduction of vasodilators - nitric oxide and prostaglandins (10,11). Excretion contrast-

substance requires a significant amount urine to remove the osmotic load. The functioning of the kidney under conditions of high osmotic load leads to characteristic histopathological

logical changes, called "osmotic sky nephrosis". Changes specific to osmotic nephrosis were detected in 22.3% biopsies performed on patients during 10 days after the introduction of a contrast agent properties (12). After the introduction of a contrast agent a transient increase in renal blood current followed by a longer its decrease is observed in animals and humans(13). Endothelin-1 is considered the most likely cause of changes in most

research (14,15). Vasoactive the effect of adenosine on various organs depends on sites on the ratio of its A1 and A2 receptors. IN kidneys, unlike the heart, adenosine causes

causes vasoconstriction. They also think that he plays a role in the pathogenesis of CIN due to an increase its concentration in the kidney as a result of increased slow hydrolysis of adenosine triphosphate (16).Free oxygen radicals that form during hypoxia, are also likely to contribute

contribution to kidney damage (17)

RISK FACTORS OF CONTRAST INDUCED NEPHROPATHY

Risk factors for the development of CIN have been well studied chen in several studies and summarized in final table (Table 1). They can be di-divided into two categories: fixed (nemo-

modified) and modifiable.The following non-modified cited risk factors for CIN: elderly

growth, diabetes mellitus, previous renal insufficiency, congestive heart failure stagnation, hemodynamic instability, and nephrotic syndrome.

1.Age

Performing contrast studies in elderly patients is associated with increased risk of contrast-induced nephropathy. In a study by Rich et al. in patients older than 70 years, CIN developed in 11% of the study data (3). Reasons for higher risk

development of CIN in the elderly have not been studied and probably have multifactorial

toric nature, including age-related changes decrease in renal function with a decrease in the rate glomerular filtration rate (GFR), tubular secretion and concentration ability,

as well as a more difficult puncture of the vessel, requiring giving more contrast, the presence

multivessel lesion, etc. Important, that in multivariate analysis, by itself

growing older than 70 in some studies was an independent predictor of the development of CIN

(18,19,20).

2.Previous kidney failure

Chronic renal failure (CRF),now included in the supranosological concept - chronic kidney disease (CKD), with increased serum creatinine level – critical risk factor for the development of CIN, the frequency of which swarm is extremely high, ranging from 14.8% up to 55% (4,5,21). With multivariate analysis baseline creatinine levels in most studies turned out to be an independent predictor rum CIN (3,4,5,21). As opposed to risk development of oil recovery factor turned out to be minimal (less than 10%) in patients who had a normal function

the kidneys during the study with the introduction contrast agent.

High baseline creatinine values were associated with an increased risk of CIN (22). As shown in

in their study by Hall et al. (23), at initial bottom creatinine level less than 1.2 mg/dl frequency

ORF was only 2%. However, in patients with the level of initial creatinine from 1.4 to 1.9 mg /

for the frequency of CIN increased to 10.4%, and in patients those who had initial creatinine more than 2.0 mg /dl, after angiography CIN developed in 62%.CIN risk prediction model according to the level of initial serum creatinine shows exponential social increase in the frequency of nephrotoxicity at baseline levels greater than 1.2 mg/dL (24). IN

in general, the estimated rate of glomerular filtration rate (GFR), which is less than

60 ml / min / 1.73m², is considered borderline in relation to increase in the development of CIN (25).

3.Diabetes

In numerous studies (3,4,5,26) diabetes mellitus was defined as independent the most predictor of the risk of developing CIN.The incidence of CIN in patients with diabetes mellitus flashes from 5.7 to 29.4% (2,27,28).

What is the prevalence of diabetes in the general population and its ability to cause a wide range of cardiovascular disease requiring imaging studies to correct diagnostics and treatment, patients suffering from DM represent a significant proportion among

individuals undergoing contrast studies.It is interesting to note that the risk of CIN increases in

patients with diabetes even with preserved kidney function(26.29). The presence of other risk factors such as like kidney failure or proteinuria,patients with diabetes further increases the likelihood development of CIN. In a study by Berns et al. (1)CIN occurred in 27% of DM patients with baseline creatinine level from 2.0 to 4.0 mg/dl, and had 81% of diabetic patients with baseline creatinine more than 4.0 mg/dl. In a study by Toprak et al. (30) in 421 patients, the estimated level was reduced creatinine clearance value, being in the range

from 15 to 60 ml / min according to the Cockcroft-Gault formula.When dividing these patients into 3 groups according to fasting blood glucose levels it turned out that in the group with a normal value "fasting" glucose (n = 144; glucose less than 100mg/dl) CIN (determined within 48 hours after angiography as an increase in the level of creatinine more than 25% of the initial value) was in 5.5% patients, while those with prediabetic state (n = 140; glucose from 100 to 125mg/dl) CIN was in 11.4%, and in patients with DM (n =137; glucose over 125 mg/dl) CIN was observed in 20% of cases (30).

4.Anemia

In a large register, consisting of 6773 pain-patients who have consecutively undergone percutaneous coronary intervention, with multifactorial nom regression analysis initially low

hematocrit was identified as an independent pre-CIN development speaker (29). CIN (defined

as an increase over the next 48 hours after serum creatinine angiography 25% or 0.5 mg/dl or more) increased from 10.3% in the highest hematocrit quintile before 23.3% in the lowest hematocrit quintile (P for trend <0.0001).

5. Condition after transplant kidneys.

Concomitant use of nephrotoxic drugs (eg, cyclosporine) along with a high incidence of diabetes and renal insufficiency in patients undergoing kidney transplantation is “favorable background for a high risk of developing CIN. Ahuja et al. (33) retrospectively estimated results of studies with the introduction of con-trust in 144 patients with functioning renal allograft. It turned out, that the overall frequency of CIN in the group was 21.2%, and it was especially high (42.8%)

among those who were not hydrated before con-trust research.

6. The amount of injected contrast.

The volume of contrast injected during the study substance is of paramount importance

in the development of CIN (28). This is the main submitter-change in the risk factor for CIN. However, growth the complexity of coronary interventions is inevitable causes an increase in the use of con-trust substances during the procedure, and, consequently, importantly, increases the risk of CIN. Correlation the relationship between the amount of injected contrast of matter and an increase in the frequency of SIF was a has been reported in many studies (34,35).

According to McCullough et al. (5) risk CIN is minimal in patients who received less 100 ml of contrast agent. induced nephropathy.

Focus on prevention.

High baseline creatinine values were associated with an increased risk of CIN (22). As shown in

in their study by Hall et al. (23), at initial bottom creatinine level less than 1.2 mg/dl frequency

ORF was only 2%. However, in patients with the level of initial creatinine from 1.4 to 1.9 mg /

for the frequency of CIN increased to 10.4%, and in patients those who had initial creatinine more than 2.0 mg /dl, after angiography CIN developed in 62%. CIN risk prediction model according to the level of initialth serum creatinine shows exponential social increase in the frequency of nephrotoxicity at baseline levels greater than 1.2 mg/dL (24). IN in general, the estimated rate of glomerular filtration rate (GFR), which is less than 60 ml / min / 1.73m², is considered borderline in relation to increase in the development of CIN (25).

CONCLUSION

Contrast-induced nephropathy - iatrogenic pathology that develops after the introduction of

contrast agents. Straight cytotoxic effect of renal tissue, induced by a contrast agent, along with decrease in renal blood flow are the most

obvious links in the pathogenesis of CIN, while other arrangements are still

poorly studied. Although the frequency of CIN in the general population treatment of patients receiving contrast is definitely low, it manifests itself in a significant number of patients with existing chronic kidney disease, in patients with diabetes even in the elderly. The presence of several risk factors increases the likelihood of acute kidney injury after administration of contrast substance. Currently the best CIN prevention strategy is to identify treatment of patients with risk factors, and also conduct adequate periprocedural hydration. The role of various drugs in prevention of CIN is still controversial and suggests future research. Despite the remaining discrepancies regarding the degree of nephro-toxicity of various contrast agents, in present clinical practice should be read isosmolar and low osmolar

contrast agents, strictly avoiding highly osmolar contrast agents in patients with impaired kidney function.

References.

1. ASPECTS OF PREDICTION OF CHRONIC KIDNEY DISEASE IN OUTPATIENT CONDITIONS. AKHMEDOVA NILUFAR SHARIPOVNA, RAVSHANOV SARDOR SHARIPOVNA Elektronniy nauchniy jurnal "Biologiya i integrativnaya meditsina" №2 (55) 2022.

2. PREVALENCE, RISK FACTORS AND ORGANIZATION OF CARE FOR CHRONIC KIDNEY DISEASES AKHMEDOVA NILUFAR SHARIPOVNA Elektronniy nauchniy jurnal "Biologiya i integrativnaya meditsina" №5 (45) 2020

3. Rich M.W., Crecelius C.A. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch. Intern. Med., 1990, 150, 1237-1242.

4. Rihal C.S., Textor S.C., Grill D.E. et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation, 2002, 105, 2259-2264.

5. McCullough P.A., Wolyn R., Rocher L.L. et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to death. Am. J. Med., 1997, 103, 368-375.

6. Messana J.M., Cieslinski D.A., Humes H.D. Comparison of toxicity of radiocontrast agents to renal tubule cells in vitro. Ren. Fail., 1990, 12, 75-82.

7. Katholi R.E., Woods W.T. Jr., Taylor G.J. et al. oxygen free radicals and contrast nephropathy. *Am. J. Kidney. Dis.*, 1998,32, 64-71.
8. Ermolenko V.M. Acute renal failure. In book. *Nephrology: A Guide for Physicians*. In 2 volumes.
T.1. Under the editorship of I.E. Tareeva. M., *Medicine*, 1995, p.309.
9. Bakris G.L., Lass N., Gaber A.O. et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. *Am. J. Physiol.*, 1990, Jan, 258 (1 Pt 2), F115-20.
10. Heyman S.N., Reichman J., Brezis M. Pathophysiology of radiocontrast nephropathy: A role for medullary hypoxia. *Invest. Radiol.*, 1999, 34, 685-691.
11. Solomon R. Contrast-medium-induced acute renal failure. *Kidney Int.*, 1998, 53, 230-242.
12. Moreau J.F., Droz D., Noel L.H. et al. Tubular nephrotoxicity of water-soluble iodinated contrast media. *Invest. Radiol.*, 1980, 15(6 Suppl), S54-S60.
13. Rauch D., Drescher P., Pereira F.J. et al. Comparison of iodinated contrast media-induced renal vasoconstriction in human, rabbit, dog, and pig arteries. *Invest. Radiol.*, 1997, 32, 315-319.
14. Klause N., Arendt T., Lins M., et al. Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man. *Adv. Exp. Med. Biol.*, 1998, 454, 225-234.
15. Clark B.A., Kim D., Epstein F.H. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. *Am. J. Kidney Dis.*, 1997, 30, 82-86.
16. Elkayam U., Mehra A., Cohen G. et al. Renal circulation effects of adenosine in patients with chronic heart failure. *J. Am. Coll. Cardiol.*, 1998, 32, 211-215.
17. Sandhu C., Newman D.J., Morgan R. et al. The role of oxygen free radicals in contrast induced nephrotoxicity. *Acad. Radiol.*, 2002, 9 (Suppl 2), S436-S437.
18. Gussenhoven M.J., Ravensbergen J., van Bockel J.H. et al. Renal dysfunction after angiography: A risk factor analysis in patients with peripheral vascular disease. *J. Cardiovasc. Surg. (Torino)*, 1991, 32, 81-86.
19. Kini A.S., Miter C.A., Kim M. et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: Effect of selective dopamine receptor agonist fenoldopam. *Cardiovasc. Interv.*, 2002, 55, 169-173.
20. Heller C.A., Knapp J., Halliday J. et al. failure to demonstrate. Contrast nephrotoxicity. *Med. J. Aust.*, 1991, 155, 329-332.